Xoma Neuprex License Lifts Stock As Investors Return To Small-Cap Biotech
Xoma returned to favor on Wall Street with a $35 mil. licensing deal for Neuprex (rBPI-21), giving Baxter worldwide rights to the bactericidal/permeability-increasing protein product for meningococcemia and all future antibacterial and anti-endotoxin indications.
You may also be interested in...
Ilex Oncology's combination of contract research and a proprietary pipeline is finding favor on Wall Street as the CRO industry overall weathers a slump.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials